Recognition by the European Crohn’s and Colitis Organisation marks a major step forward for evidence-based integrative care in ulcerative colitis and Crohn’s disease.

Evinature announced that the compounds of its CurQD® Protocol have been formally incorporated into the 2025 ECCO Guidelines on Dietary Management of IBD, published in the Journal of Crohn’s & Colitis. This inclusion represents a significant global endorsement, recognizing CurQD® as a scientifically supported, adjunct therapy for patients with ulcerative colitis and Crohn’s disease.

“This recognition by the ECCO nutritional guidelines represents a defining moment for CurQD® and for patients seeking clinically validated, natural treatment options,” said Nir Salomon, Cofounder of Evinature. “It validates years of rigorous research and highlights the potential for integrative approaches to complement conventional IBD care.”

The ECCO Guidelines are among the most trusted references in gastroenterology worldwide. Developed by leading experts, they guide clinicians in diagnosing, managing, and treating IBD, influencing care for millions of patients worldwide. This recognition in the guidelines positions CurQD® as a valid option within the standard of care in IBD, providing physicians and patients with a credible, evidence-based natural therapy.

From Scientific Forum to Clinical Recommendation

CurQD®’s journey to guideline inclusion began with its presentation at the ECCO Congress in Berlin in February 2025, the leading international forum for IBD research. There, the protocol was highlighted among emerging nutritional and adjunct therapies, drawing attention for its evidence-backed outcomes in both ulcerative colitis and Crohn’s disease.

Following the congress, ECCO formally incorporated the CurQD® compounds into its published nutritional guidelines, cementing its role as a validated therapeutic option.

“The inclusion in ECCO consensus underscores the growing acceptance of research-supported, integrative approaches in IBD care,” said Prof. Shomron Ben-Horin, MD, Director of Gastroenterology at Sheba Medical Center & Chief Scientist at Evinature. “CurQD® demonstrates how an evidence-based nutraceutical can successfully complement conventional therapies, improving patient outcomes and supporting long-term remission.”

Evidence-Based Impact

The ECCO Guidelines reference multiple studies that established the clinical effectiveness of the compounds of CurQD. One of the first landmark studies, conducted across five academic centers, focused on adults with active ulcerative colitis, including patients who had previously been treated with or failed biologic therapies. Published in 2023, the study reported:

• 60.2% of patients achieved a clinical response
• 46.5% reached clinical remission
• 59% experienced normalization of fecal calprotectin
  
   

These findings demonstrated that CurQD® could achieve meaningful clinical outcomes even in drug-refractory patients, offering a safe, natural alternative for patients seeking sustained disease control.

Significance for Patients

For individuals living with IBD, the ECCO recognition of CurQD® validates an accessible, research-backed option that supports long-term gut health and symptom management. The protocol offers an integrative approach that can complement existing therapies, helping patients achieve sustainable remission while maintaining quality of life.

Advancing Integrative Care

CurQD®’s recognition in the ECCO nutritional Guidelines marks a key milestone in integrating natural, evidence-based protocols into modern IBD management. It reinforces Evinature’s mission to bridge rigorous scientific research with therapeutic approaches that empower patients and clinicians alike to pursue safe, effective, and personalized care strategies.

By offering a validated adjunct therapy, Evinature continues to advance the standard of care in IBD, demonstrating that natural interventions can coexist with conventional treatments to improve clinical outcomes and enhance patient well-being.